Convert the tumor's shield into the very weapon that defeats it
Cancer has long exploited the body's own immune cells as unwitting collaborators, turning macrophages into guardians of the tumor rather than its destroyers — a betrayal that has blunted the promise of immunotherapy for many patients. Scientists at the Weizmann Institute of Science have now engineered molecules called MiTEs that interrupt this arrangement, simultaneously disabling tumor-protecting macrophages and awakening dormant killer immune cells, while built-in molecular masks ensure the immune response ignites only at the tumor site. The work represents a shift in oncological thinking: rather than attacking cancer directly, it seeks to dismantle the sanctuary cancer has built for itself within the body's own defenses.
- A critical flaw in immunotherapy — that tumors recruit macrophages carrying the TREM2 receptor to actively suppress immune attacks — has been identified as a key reason many patients fail to respond to existing treatments.
- The danger of simply destroying these macrophages outright is real: blunt immune interventions risk triggering systemic damage, turning the body's defenses against healthy tissue as well as cancerous cells.
- MiTEs thread this needle by combining two actions in one molecule — blocking TREM2 on tumor-allied macrophages while simultaneously delivering an activation signal to killer immune cells positioned right beside them.
- Molecular masks built into MiTEs keep the immune-activating cytokine IL-2 dormant in the bloodstream, releasing it only when tumor-specific enzymes strip the mask away, confining the immune response to the tumor microenvironment.
- In mouse models and human renal carcinoma tissue samples, MiTEs shrank tumors and revived exhausted killer cells, with early evidence suggesting amplified effect when combined with chemotherapy, radiation, and checkpoint inhibitors.
- Clinical trials are being planned to test long-term safety and combination strategies, with the approach's reliance on immune mechanisms common across cancer types raising hopes for broad applicability.
Cancer has learned to hide — not only by evading the immune system, but by recruiting it. Macrophages, normally vigilant defenders of the body's tissues, often switch allegiances inside tumors, suppressing the very immune responses that might destroy the cancer. This is a central reason so many patients fail to benefit from immunotherapy even when the treatment works for others.
Researchers at the Weizmann Institute of Science traced this betrayal to a receptor called TREM2, which appears in unusually high concentrations on tumor-protecting macrophages and functions like a dimmer switch on anti-cancer immunity. Patients whose tumors recruit these cells tend to fare worse. The team, led by Michelle von Locquenghien, Pascale Zwicky, and Ken Xie in Ido Amit's lab, asked whether that switch could be flipped back.
Their answer was MiTEs — Myeloid-targeted immunocytokines and natural killer/T-cell Enhancers — engineered molecules that do two things at once: block the TREM2 receptor on tumor-allied macrophages and deliver an activation signal to nearby killer immune cells. Advanced imaging revealed that TREM2-carrying macrophages are often positioned directly beside exhausted killer cells, as though the tumor had strategically placed its suppressors next to the weapons most capable of destroying it. MiTEs exploit that proximity.
The safety design is equally important. Broad immune activation across the body can be catastrophic, causing the immune system to attack healthy tissue. To prevent this, the researchers built molecular masks into MiTEs that keep the activating cytokine IL-2 dormant during circulation. Only tumor-specific enzymes can remove the mask, ensuring the immune response fires locally and precisely.
In mouse studies, MiTEs shrank tumors and triggered deep immune remodeling. In human renal carcinoma tissue, they revived dormant killer cells. Because the approach targets immune mechanisms shared across many cancer types rather than tumor-specific features, it may prove broadly applicable. Clinical trials are now being planned to evaluate long-term safety and combinations with existing therapies — early signals suggest MiTEs amplify rather than compete with current treatments, pointing toward a new generation of immunotherapy that defeats cancer by dismantling the shelter it has built inside the body's own defenses.
Cancer has learned to hide. It does this partly by turning the body's own defenders against it—specifically, a type of immune cell called a macrophage that normally patrols tissues looking for trouble. When these cells end up inside a tumor, they often switch sides. They stop attacking the cancer and start protecting it, suppressing the very immune response that might kill it. This is why many patients fail to respond to immunotherapy, even when the treatment works brilliantly for others.
Researchers at the Weizmann Institute of Science have identified the mechanism behind this betrayal. They found that tumor-protecting macrophages carry an unusually high amount of a receptor called TREM2, which acts like a dimmer switch on anti-cancer immunity. Patients whose tumors recruit these TREM2-heavy macrophages tend to survive shorter and respond poorly to treatment. The question became: could you flip that switch back on?
Instead of trying to kill these macrophages outright—a blunt approach that risks collateral damage—the Weizmann team decided to reprogram them. Led by Michelle von Locquenghien, Pascale Zwicky, and Ken Xie in Ido Amit's lab, they engineered a new class of molecules called MiTEs, short for Myeloid-targeted immunocytokines and natural killer/T-cell Enhancers. The design is elegant: MiTEs simultaneously block the TREM2 receptor on tumor-allied macrophages while delivering an activation signal to killer immune cells, waking them up to attack the cancer.
The real innovation lies in the safety mechanism. Activating the immune system too broadly across the body can backfire catastrophically—the immune system loses its ability to distinguish enemy from ally and begins destroying healthy tissue. To prevent this, the researchers built molecular masks into the MiTEs. These masks keep the immune-activating component, a cytokine called IL-2, dormant while the molecules circulate through the bloodstream. Only when MiTEs reach the tumor do special enzymes present at that site remove the mask, unleashing the activation signal precisely where it is needed. The immune response stays local, confined to the tumor itself.
The spatial architecture of the tumor proved crucial to this design. Using advanced imaging techniques that reveal where genes are active at single-cell resolution, the researchers discovered that TREM2-carrying macrophages often sit directly next to exhausted killer immune cells—as if the cancer had strategically positioned its suppressors right next to the weapons that could destroy it. MiTEs exploit this proximity, blocking the suppressors while energizing the weapons in the same location.
In mouse studies, MiTEs shrank tumors and triggered widespread immune remodeling in both macrophages and killer cells. When tested on tissue samples from patients with renal cell carcinoma, they provoked robust immune activation, awakening dormant killer cells. The approach works through immune mechanisms common to many cancers rather than targeting tumor-specific features, which suggests it could have broad applicability across different cancer types and different patients.
The Weizmann team is now planning clinical trials to assess long-term safety and to test whether MiTEs work synergistically with existing therapies—chemotherapy, radiation, and checkpoint inhibitors. Early results suggest they do amplify the overall immune response when combined with current treatments. The vision is a new generation of immunotherapies that reshape the tumor's microenvironment rather than simply trying to kill cancer cells directly, converting the tumor's own defenses into the very mechanism of its defeat.
Citações Notáveis
Tumors hijack macrophages to suppress immune responses and promote their own growth. Our goal has been to re-educate these cells rather than remove them.— Prof. Ido Amit, Weizmann Institute
The future of immunotherapy lies in combining safety with precision—reprogramming the immune ecosystem from the inside rather than targeting cancer cells directly.— Prof. Ido Amit
A Conversa do Hearth Outra perspectiva sobre a história
Why does the immune system fail against cancer in the first place? It seems like it should recognize a tumor as a threat.
Cancer is patient. It doesn't just hide—it actively recruits the body's own peacekeeping cells and convinces them to stand guard. The macrophages that end up in tumors aren't defective; they're reprogrammed. The cancer essentially flips a switch on them.
And this TREM2 receptor is that switch?
It's more like the mechanism that keeps the switch flipped. When macrophages express high levels of TREM2, they become very good at suppressing the immune response. Patients with tumors full of these cells don't do well with current immunotherapy.
So instead of removing these macrophages, you're trying to flip them back?
Exactly. Removing them is messy—you lose their useful functions elsewhere in the body. Reprogramming them means you block their tumor-protecting activity while simultaneously waking up the killer cells they were suppressing. It's more surgical.
The molecular mask is clever. Why not just activate the immune system everywhere?
Because the immune system can't tell the difference between cancer and healthy tissue if you activate it too broadly. You end up with autoimmune damage—the body attacking itself. The mask ensures activation only happens at the tumor site, where those special enzymes exist.
How did you figure out where to position this therapy?
Spatial transcriptomics showed us the physical layout of the tumor's immune architecture. We saw that exhausted killer cells were sitting right next to the TREM2 macrophages. That told us we could target both at once, in the same location.
What happens next?
Clinical trials. We need to know if this is safe long-term in humans, and whether it works better when combined with existing treatments. The early signs suggest it amplifies other immunotherapies, which is promising.